The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland
- PMID: 27882823
- DOI: 10.1080/14737167.2017.1262767
The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland
Abstract
Background: The appropriate access to public information is very important for healthcare system stakeholders. The goal of this study was to examine how the execution of the formally existing right to public information on the HTA-based recommendations on reimbursement of new health technologies from public funds has been changing in Poland.
Methods: All recommendations published within two predefined equal periods of time between 2013 and 2015 were analyzed. The gathered data was subjected to statistical analysis.
Results: The frequency and intensity of censoring the published HTA-based recommendations on the pharmaceutical reimbursement has diminished. The text readability and clarity of message has improved, although the degree of decisiveness of the recommendations has dropped.
Conclusion: The positive changes in the public communication policy should be continued. The transparency of the HTA-based recommendations should be increased further in some areas in the future.
Keywords: HTA; Health technology assessment; Poland; citizens’ rights; pharmaceutical reimbursement; public information; transparency.
Similar articles
-
From idealistic rookies to a regional leader: the history of health technology assessment in Poland.Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:156-62. doi: 10.1017/S0266462309090588. Epub 2009 Jun 16. Int J Technol Assess Health Care. 2009. PMID: 19527537
-
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency.Expert Rev Pharmacoecon Outcomes Res. 2025 Feb;25(2):265-273. doi: 10.1080/14737167.2024.2416240. Epub 2024 Oct 21. Expert Rev Pharmacoecon Outcomes Res. 2025. PMID: 39431604
-
Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):197-205. doi: 10.1080/14737167.2018.1384696. Epub 2017 Oct 5. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 28952400
-
Health technology assessment in Saudi Arabia.Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):393-402. doi: 10.1080/14737167.2018.1474102. Epub 2018 May 16. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 29733227 Review.
-
Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.Value Health Reg Issues. 2018 Sep;16:81-91. doi: 10.1016/j.vhri.2018.08.002. Epub 2018 Oct 11. Value Health Reg Issues. 2018. PMID: 30316029 Review.
Cited by
-
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.Healthcare (Basel). 2024 Apr 25;12(9):889. doi: 10.3390/healthcare12090889. Healthcare (Basel). 2024. PMID: 38727447 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical